ATIP-Avenir Group

1. Lord, C. J. & Ashworth, A. The DNA damage response and cancer therapy. Nature 481, 287–294 (2012). CAS PubMed Article PubMed Central Google Scholar 2. Tubbs, A. & Nussenzweig, A. Endogenous DNA damage as a source of genomic instability in cancer. Cell 168, 644–656 (2017). CAS PubMed PubMed Central Article Google Scholar 3. Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015). CAS PubMed PubMed Central Article Google Scholar 4. Le, D. T. et al.

To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 Chemical structure of BAY 1238097. Fig. 2 Clinical pharmacokinetic parameters of BAY 1238097. AUC(0–72) (left) and Cmax values (right) are indicated for plasma samples from each of the patients at each of the three BAY 1238097 dose levels on cycle 1, day −7; cycle 1, day 1 and cycle 2, day 1.